CN105130872B - 一种3位三氟甲基取代吲哚的制备方法 - Google Patents

一种3位三氟甲基取代吲哚的制备方法 Download PDF

Info

Publication number
CN105130872B
CN105130872B CN201510527880.2A CN201510527880A CN105130872B CN 105130872 B CN105130872 B CN 105130872B CN 201510527880 A CN201510527880 A CN 201510527880A CN 105130872 B CN105130872 B CN 105130872B
Authority
CN
China
Prior art keywords
reaction
acetyl
trifluoromethyl
phenyl
trifluoromethyls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201510527880.2A
Other languages
English (en)
Other versions
CN105130872A (zh
Inventor
周宜荣
张春艳
杨琴
彭以元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Normal University
Original Assignee
Jiangxi Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Normal University filed Critical Jiangxi Normal University
Priority to CN201510527880.2A priority Critical patent/CN105130872B/zh
Publication of CN105130872A publication Critical patent/CN105130872A/zh
Application granted granted Critical
Publication of CN105130872B publication Critical patent/CN105130872B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

本发明公开了一种3位三氟甲基取代吲哚的制备方法,采用各种取代的乙酰苯胺作为反应底物,其反应收率可达到中等到优秀,反应的化学选择性优秀,区域选择性高,检测中没有监测到另一个同分异构体(2位三氟甲基取代吲哚)产生,其条件温和,底物的适用范围广(其中R=H或CH3、OCH3、SCH3等各种供电子基团,以及NO2、Cl等各种吸电子基团,Ar=各种取代的苯环)、其操作简便、成本较低、副反应少、产品纯度高、便于分离提纯和可适用于较大规模的制备,所以其所得的产物具有非常好的生物医药领域的应用前景。

Description

一种3位三氟甲基取代吲哚的制备方法
技术领域
本发明涉及有机化学领域,尤其涉及一种3位三氟甲基取代吲哚的制备方法。
背景技术
吲哚骨架是众多天然产物和药物的的核心结构,吲哚杂环化合物具有广谱的生理和药物活性,所以吲哚类化合物的快速高效合成及其多样性修饰一直吸引着有机化学家和药物化学家的研究兴趣((a)Kaushik,N.K.;Kaushik,N.;Attri,P.;Kumar,N.;Kim,C.H.;Verma,A.K.;Choi,E.H.Molecules,2013,18,6620.(b)Patel,H.;Darji,N.;Pillai,J.;Patel,B.Int.J.Drug Res.Tech.2012,2,225.(c)Biswal,S.;Sahoo,U.;Sethy,S.;Kumar,H.K.S.;Banerjee,M.Asian J.Pharm.Clin.Res.2012,5,1.(d)Kochanowska-Karamyan,A.J.;Hamann,M.T.Chem.Rev.2010,110,4489.(e)d’Ischia,M.;Napolitano,A.;PezzellaA.in Comprehensive Heterocyclic Chemistry III,Vol.3,Elsevier,Oxford,2008.(f)Eicher,T.;Hauptmann,S.;Speicher,A.The Chemistry of Heterocycles,Wiley-VCHVerlag GmbH&Co,Weinheim,2nd edn,2003.(g)Sundberg,R.J.Indoles,Academic Press,San Diego,1996.)。其实早在1883年,Fisher等人就发展了著名的Fisher吲哚合成反应(Fischer,E.;Jourdan,F.Ber.Dtsch.Chem.Ges.1883,16,2241.),之后不断有化学家报道吲哚的改进合成方法((a)Guo,T.;Huang,F.;Yu,L.;Yu,Z.Tetrahedron Lett.2015,56,296.(b)Inman,M.;Moody,C.J.Chem.Sci.2013,4,29.(c)Yoshikai,N.;Wei,Y.AsianJ.Org.Chem.2013,2,466.(d)Shi,Z.;Glorius,F.Angew.Chem.,Int.Ed.2012,51,9220.(e)Platon,M.;Amardeil,R.;Djakovitch,L.;Hierso,J.-C.Chem.Soc.Rev.2012,41,3929.(f)Taber,D.F.;Tirunahari,P.K.Tetrahedron 2011,67,7195.(g)Cacchi,S.;Fabrizi,G.Chem.Rev.2011,111,PR215.)。最近过渡金属催化直接碳氢键活化,由于其具有底物不需要预活化,选择性好,效率高等特别,成为有机化学研究的新热点((a)Yu,J.;Shi,Z.C–HActivation,Springer,2010.(b)Hussain,I.;Singh,T.Adv.Synth.Catal.2014,356,1661.(c)McGlacken,G.P.;Bateman,L.M.Chem.Soc.Rev.2009,38,2447.(d)Kakiuchi,F.;Chatani,N.Adv.Synth.Catal.2003,345,1077.(e)Ritleng,V.;Sirlin,C.;Pfeffer,M.Chem.Rev.2002,102,1731.)。Fagnou小组在2008年和2010年分别报道了以乙酰苯胺化合物和内炔为起始原料,通过铑催化,有效合成吲哚化合物((a)Stuart,D.R.;Bertrand-Laperle,M.;Burgess,K.M.N.;Fagnou,K.J.Am.Chem.Soc.,2008,130,16474.(b)Stuart,D.R.;Alsabeh,P.;Kuhn,M.;Fagnou,K.J.Am.Chem.Soc.,2010,132,18326.)。我们小组一直对含氮杂环化合物的合成及其药物活性有较为系统的研究,最近我们报道了铜催化邻溴苯甲醛和甘氨酸酯盐酸盐一锅法合成得到2-羧酸酯取代的吲哚化合物,在温和的反应条件下获得了中等到优良的产率(Zhu,Z.;Yuan,J.;Zhou,Y.;Yang,Q.;Xu,J.;Peng,Y.Eur.J.Org.Chem.2014,511.)。
与此同时,我们注意到,三氟甲基是一个具有许多优异性能的基团,普遍存在于各种新药物和新材料中。由于氟原子的特殊性,往往给这些新药物和新材料带来意想不到的效果和性能。因此,研究和发展一些简单有效的方法合成3位三氟甲基取代吲哚化合物具有十分重要的科学意义和应用价值。然而,文献报道的合成此类化合物的方法却十分有限,并且反应都存在着一些局限性,难以大规模生产和应用。目前的研究主要集中在对吲哚环骨架的改造。国内外不同课题组发展了各自的催化体系,通过不同的三氟甲基化试剂在吲哚环上成功引入三氟甲基基团((a)Gonda,Z.Kovács,;S.;Wéber,C.;Gáti,T.;Mészáros,A.;Kotschy,A.Org.Lett.2014,16,4268.(b)Pitre,S.P.;McTiernan,C.D.;Ismaili,H.;Scaian,J.C.ACS Catal.2014,4,2530.(c)Xu,C.;Liu,J.;Ming,W.;Liu,Y.;Liu,J.;Wang,M.;Liu,Q.Chem.Eur.J.2013,19,9104.(d)Chu,L.;Qing,F.L.J.Am.Chem.Soc.2012,134,1298.(e)Iqbal,N.;Choi,S.;Ko,E,;Cho,E.J.Tetrahedron Lett.2012,53,2005.(f)Zhang,C.;Wang,Z.;Chen,Q.;Zhang,C.;Gu,Y.;Xiao,J.C.Angew.Chem.Int.Ed.2011,50,1896.(g)Mu,X.;Chen,S.;Zhen,X.;Liu,G.S.Chem.Eur.J.2011,17,6039.)。我们小组基于在过渡金属催化直接碳氢键官能团化研究的工作基础,设想能否直接从三氟甲基砌块出发,在构筑吲哚环的过程中,一步引入三氟甲基基团,避免后续的衍生化过程。经过仔细的文献调研,我们发现只有一例相关报道:2004年Konno小组通过钯催化邻碘苯胺和三氟甲基炔偶联再环化的串联反应,成功制备了2位或者3位有三氟甲基取代的吲哚化合物。但是此反应具有一定的限制,例如:底物范围不广,起始原料邻碘苯胺获得不易,反应区域选择性不高,催化剂用量大,反应时间长,原子经济性不高等,大大限制该反应的实际使用价值(Konno,T.;Chae,J.;Ishihara,T.;Yamanaka,H.J.Org.Chem.,2004,69,8251.)。
因此,本发明旨在报道一类利用过渡金属催化的直接碳氢活化的串联氧化环化反应,从乙酰苯胺和三氟甲基苯乙炔出发,在比较温和的条件下高效率、高选择性地合成3位三氟甲基取代吲哚化合物的新技术。
发明内容
本发明的目的在于提供一种3位三氟甲基取代吲哚的制备方法,本方法反应条件温和、操作简便、成本较低、副反应少、产品纯度高和便于分离提纯,可适合于较大规模的制备,所得产物具有潜在的生物和药物活性,因此可应用于生物医药领域,具有非常好的应用前景。
本发明是这样实现的,一种3位三氟甲基取代吲哚的制备方法,其实现的步骤为:采用各种取代的乙酰苯胺作为反应底物,使其与一系列三氟甲基苯乙炔在二氯(五甲基环戊二烯基)合铑(III)二聚体([RhCp*Cl2]2)催化条件下,通过一个直接碳氢活化的串联氧化环化反应,其反应温度为100-120℃,反应时间为1小时,之后高效制得3位三氟甲基取代吲哚化合物,所述各种取代的乙酰苯胺为乙酰苯胺的苯环上可以有各种取代基团,所述一系列三氟甲基苯乙炔为三氟甲基苯乙炔的苯环上可以有各种取代基团。
所述各种取代的乙酰苯胺与三氟甲基苯乙炔的比例为1:2。
上述步骤中所使用的有机溶剂为叔戊醇、环己醇、1,2-二氯乙烷、硝基甲烷或甲苯。
上述步骤中所使用的催化剂为二氯(五甲基环戊二烯基)合铑(III)二聚体。
上述步骤中所使用的氧化剂为醋酸铜。
上述步骤中所使用的添加剂为六氟锑酸银、三氟甲基磺酸银、氧化银或硝酸银。
上述步骤中反应方程式如下:
其中R=H或CH3、OCH3、SCH3等各种供电子基团,以及NO2、Cl等各种吸电子基团;Ar=各种取代的苯环。
本发明的技术效果是:本发明方法的反应收率可达到中等到优秀,反应的化学选择性优秀,区域选择性高,检测中没有监测到另一个同分异构体(2位三氟甲基取代吲哚)产生,其条件温和,底物的适用范围广(其中R=H或CH3、OCH3、SCH3等各种供电子基团,以及NO2、Cl等各种吸电子基团,Ar=各种取代的苯环)、其操作简便、成本较低、副反应少、产品纯度高、便于分离提纯和可适用于较大规模的制备,所以其所得的产物具有非常好的生物医药领域的应用前景。
附图说明
图1为N-乙酰-3-三氟甲基-2-苯基-5-甲基吲哚化合物3d的X-单晶衍射结构图。
图2为N-乙酰-3-三氟甲基-2-苯基-5-甲基吲哚化合物3d单晶结构对应的化合物分子结构图。
具体实施方式
下面将结合附图实施例详细说明本发明所具有的有益效果,旨在帮助阅读者更好地理解本发明的实质,但不能对本发明的实施和保护范围构成任何限定。
本发明的具体操作为:向反应试管中分别依次加入乙酰苯胺,催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体(2.5mol%),氧化剂醋酸铜(2.0equiv),添加剂六氟锑酸银(10mol%AgSbF6)和溶剂叔戊醇(2mL),最后加入三氟甲基苯乙炔(2.0equiv),用橡胶塞密封反应试管。把试管油浴置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应。后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物3位三氟甲基取代吲哚。
实例1
向反应试管中分别依次加入乙酰苯胺,催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体(2.5mol%),氧化剂醋酸铜(2.0equiv),添加剂六氟锑酸银(10mol%AgSbF6)和溶剂叔戊醇(2mL),最后加入三氟甲基苯乙炔(2.0equiv),用橡胶塞密封反应试管。把试管油浴置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应。后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-吲哚化合物3a。产率:81%;黄色固体,熔点73-75℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.26(1H,d,J=8.4Hz),7.67(1H,d,J=8.0Hz),7.42-7.32(5H,m),7.30-7.25(2H,m),1.78(3H,s);13CNMR(100MHz,CDCl3,25℃,TMS):δ171.2,138.6(q,JC-F=4.1Hz),136.0,130.9,130.2,130.0,128.6,126.1,124.8,124.5,123.5(q,JC-F=266.8Hz),119.6,116.1,111.6(q,JC-F=34.5Hz),27.6;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.39;HRMS(ESI):m/z[M+Na]+calcdfor(C17H12F3NO)Na:326.0763;found:326.0772。
同样的方法得到实例2-18。
实例2
N-乙酰-3-三氟甲基-2-苯基-7-甲基-吲哚,产率:50%;黄色固体,熔点117-120℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ7.58(1H,d,J=7.6Hz),7.44-7.36(5H,m),7.19(1H,t,J=7.6Hz),7.10(1H,d,J=7.6Hz),2.27(3H,s),1.92(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ173.2,138.0(q,JC-F=4.1Hz),134.5,130.2,129.9,128.6,127.9,125.6,123.8(q,JC-F=267.4Hz),123.7,123.6,117.7,117.6,108.9(q,JC-F=34.8Hz),28.7,20.9;19FNMR(376MHz,CDCl3,25℃,TMS):δ-54.21;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NO)Na:340.0920;found:340.0929。
实例3
N-乙酰-3-三氟甲基-2-苯基-6-甲基-吲哚,产率:62%;黄色固体,熔点92-94℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.11(1H,s),7.55(1H,d,J=8.0Hz),7.41-7.35(5H,m),7.11(1H,d,J=8.0Hz),2.42(3H,s),1.78(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.4,137.9(q,JC-F=4.1Hz),136.4,136.3,131.2,130.3,129.9,128.6,125.9,123.6(q,JC-F=267.6Hz),122.7,119.2(d,JC-F=1.1Hz),116.1,111.7(q,JC-F=34.5Hz),27.6,21.9;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.47;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NO)Na:340.0920;found:340.0926。
实例4
N-乙酰-3-三氟甲基-2-苯基-5-甲基-吲哚,产率:71%;黄色固体,熔点99-100℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.16(1H,d,J=8.4Hz),7.47(1H,s),7.43-7.35(5H,m),7.16(1H,d,J=8.8Hz),2.40(3H,s),1.79(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.1,138.6(q,JC-F=4.1Hz),134.2,134.3,131.2,130.3,129.9,128.6,127.5,125.1,123.6(q,JC-F=267.5Hz),119.4(d,JC-F=1.6Hz),115.9,111.5(q,JC-F=34.4Hz),27.5,21.4;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.45;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NO)Na:340.0920;found:340.0917。
实例5
N-乙酰-3-三氟甲基-2-苯基-7-甲氧基-吲哚,产率:61%;黄色固体,熔点52-54℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ7.37-7.32(5H,m),7.18(1H,t,J=8.0Hz),6.75(1H,d,J=8.0Hz),3.86(3H,s),2.25(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ173.1,146.6,138.8(q,JC-F=3.9Hz),130.3,129.5,128.0,126.8,126.7,124.6,124.0,123.9(q,JC-F=266.8Hz),112.5,107.8(q,JC-F=35.0Hz),105.5,55.8,29.0;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.04;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NO2)Na:356.0869;found:356.0876。
实例6
N-乙酰-3-三氟甲基-2-苯基-5-甲氧基-吲哚,产率:74%;黄色固体,熔点111-113℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.20(1H,d,J=9.2Hz),7.42-7.35(5H,m),7.09(1H,s),6.94(1H,d,J=9.2Hz),3.79(3H,s),1.78(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.0,156.9,139.1(q,JC-F=4.0Hz),131.1,130.8,130.3,130.0,128.6,125.7,123.5(q,JC-F=267.6Hz),117.3,115.1,111.5(q,JC-F=34.3Hz),101.8,55.7,27.4;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.56;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NO2)Na:356.0869;found:356.0878.
实例7
N-乙酰-3-三氟甲基-2-苯基-5-甲硫基-吲哚,产率:52%;黄色固体,熔点86-88℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.28(1H,d,J=8.8Hz),7.65(1H,s),7.54-7.45(5H,m),7.37(1H,dd,J=8.8,1.6Hz),2.56(3H,s),1.88(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.0,139.2(q,JC-F=4.1Hz),134.4,134.2,130.8,130.3,130.1,128.6,126.0,125.6,123.4(q,JC-F=267.7Hz),117.9,116.6,111.1(q,JC-F=34.9Hz),27.5,17.0;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.43;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NOS)Na:372.0640;found:372.0639。
实例8
N-乙酰-3-三氟甲基-2-苯基-6-氯-吲哚,产率:71%;黄色固体,熔点85-87℃;1HNMR(400MHz,CDCl3,25℃,TMS):δ8.34(1H,s),7.57(1H,d,J=8.4Hz),7.46-7.37(5H,m),7.26(1H,dd,J=8.6,1.8Hz),1.79(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.1,139.2(q,JC-F=4.1Hz),136.3,132.2,130.5,130.2,128.7,125.2,123.3,123.2(q,JC-F=267.6Hz),120.43,120.41,116.4,111.5(q,JC-F=34.8Hz),27.5;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.52;HRMS(ESI):m/z[M+Na]+calcd for(C17H11ClF3NO)Na:360.0373;found:360.0380。
实例9
N-乙酰-3-三氟甲基-2-苯基-5,6-二氯-吲哚,产率:65%;黄色固体,熔点90-91℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.44(1H,s),7.72(1H,s),7.48-7.37(5H,m),1.79(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ170.8,140.4(q,JC-F=3.7Hz),134.5,130.5,130.3,130.1,130.0,128.8,128.7,124.3,122.9(q,JC-F=267.6Hz),120.5(d,JC-F=2.0Hz),118.1,110.9(q,JC-F=35.2Hz),27.4;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.58;HRMS(ESI):m/z[M+Na]+calcd for(C17H10Cl2F3NO)Na:393.9984;found:393.9983。
实例10
N-乙酰-3-三氟甲基-2-苯基-6-硝基-吲哚,产率:40%;白色固体,熔点198-200℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ9.18(1H,s),8.18(1H,d,J=8.8Hz),7.79(1H,d,J=8.8Hz),7.54-7.42(5H,m),1.87(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ170.7,146.0,143.5(d,JC-F=4.0Hz),134.8,130.8,130.0,129.8,129.3(d,JC-F=1.1Hz),128.9,122.9(q,JC-F=267.4Hz),119.9,119.6,112.7,111.4(q,JC-F=35.3Hz),27.4;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.44;HRMS(ESI):m/z[M+Na]+calcd for(C17H11F3N2O3)Na:371.0614;found:371.0618。
实例11
N-乙酰-3-三氟甲基-2-苯基-5-硝基-吲哚,产率:41%;棕色固体,熔点154-157℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.58(1H,s),8.37(1H,d,J=9.2Hz),8.21(1H,dd,J=9.2,2.2Hz),7.53-7.42(5H,m),1.87(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ170.9,144.6,141.8(q,JC-F=3.9Hz),138.6,130.7,130.1,129.7,128.9,124.6,122.9(q,JC-F=267.7Hz),120.8,116.4,115.8(d,JC-F=2.0Hz),111.8(q,JC-F=35.4Hz),27.4;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.44;HRMS(ESI):m/z[M+Na]+calcd for(C17H11F3N2O3)Na:371.0614;found:371.0617。
实例12
N-乙酰-3-三氟甲基-2-苯基-苯并[f]吲哚,产率:79%;黄色固体,熔点139-141℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.83(1H,s),8.10(1H,s),7.88-7.84(2H,m),7.42-7.36(7H,m),1.78(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.0,141.9(q,JC-F=4.1Hz),135.3,132.3,131.0,130.9,130.8,130.2,130.1,128.7,128.1,125.6,125.2,125.0,123.5(q,JC-F=267.7Hz),117.9,113.9,111.8(q,JC-F=34.4Hz),27.6;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.63;HRMS(ESI):m/z[M+Na]+calcd for(C21H14F3NO)Na:376.0920;found:376.0926。
实例13
N-乙酰-3-三氟甲基-2-苯基-吡咯并[2,3-G]喹啉,产率:53%;白色固体,熔点106-108℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ7.95(1H,d,J=7.6Hz),7.87(2H,t,J=8.4Hz),7.74(1H,d,J=8.4Hz),7.52-7.48(6H,m),2.45(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ175.6,137.3(q,JC-F=3.8Hz),132.1,130.7,129.9,129.7,129.5,129.4,128.4,126.4,125.3,125.1,122.7,121.8,121.5,118.5,109.2(q,JC-F=34.9Hz),29.2;19F NMR(376MHz,CDCl3,25℃,TMS):δ-53.68;HRMS(ESI):m/z[M+Na]+calcd for(C20H13F3N2O)Na:377.0872;found:377.0876。
实例14
N-乙酰-3-三氟甲基-2-苯基-苯并[g]吲哚,产率:60%;棕色固体,熔点92-94℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ7.96-7.76(4H,m),7.50(7H,s),2.26(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ175.5,137.3(q,JC-F=4.0Hz),132.0,129.8,129.7,129.5,129.4,128.4,126.4,125.3,125.1,122.7,121.8,121.4,118.4(d,JC-F=1.7Hz),108.8(q,JC-F=34.2Hz),27.4;19F NMR(376MHz,CDCl3,25℃,TMS):δ-53.70;HRMS(ESI):m/z[M+Na]+calcd for(C21H14F3NO)Na:376.0920;found:376.0925。
实例15
N-乙酰-3-三氟甲基-2-(4-氯苯基)-吲哚,产率:80%;白色固体,熔点79-82℃;1HNMR(400MHz,CDCl3,25℃,TMS):δ8.33(1H,d,J=8.4Hz),7.78(1H,d,J=8.0Hz),7.51-7.39(6H,m),1.98(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ170.8,137.2(q,JC-F=4.1Hz),136.4,136.1,131.6,129.5,129.0,128.3,126.4,124.6,123.4(q,JC-F=267.6Hz),119.8(d,JC-F=1.8Hz),116.1,112.2(q,JC-F=34.5Hz),27.8;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.40;HRMS(ESI):m/z[M+Na]+calcd for(C17H11ClF3NO)Na:360.0373;found:360.0381。
实例16
N-乙酰-3-三氟甲基-2-(4-甲基苯基)-吲哚,产率:59%;黄色固体,熔点95-97℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.27(1H,d,J=8.0Hz),7.68(1H,d,J=7.6Hz),7.36-7.21(6H,m),2.36(3H,s),1.83(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.4,140.2,139.0(q,JC-F=4.0Hz),136.0,130.1,129.3,128.0,126.0,124.9,124.4,122.3,119.6(d,JC-F=1.8Hz),116.1,111.5(q,JC-F=34.5Hz),27.6,21.4;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.40;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NO)Na:340.0920;found:340.0927。
实例17
N-乙酰-3-三氟甲基-2-(4-甲氧基苯基)-吲哚,产率:73%;黄色固体,熔点107-109℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.27(1H,d,J=8.8Hz),7.68(1H,d,J=8.0Hz),7.35-7.26(4H,m),6.92(2H,d,J=8.4Hz),3.79(3H,s),1.84(3H,s);13C NMR(100MHz,CDCl3,25℃,TMS):δ171.4,160.9,138.7(q,JC-F=4.1Hz),135.9,131.5(d,JC-F=1.0Hz),125.9,124.9,124.4,123.6(q,JC-F=267.3Hz),122.8,119.6(d,JC-F=1.8Hz),116.1,114.1,111.5(q,JC-F=34.6Hz),55.3,27.6;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.44;HRMS(ESI):m/z[M+Na]+calcd for(C18H14F3NO2)Na:356.0869;found:356.0872。
实例18
N-乙酰-3-三氟甲基-2-(4-乙酯基苯基)-吲哚,产率:64%;白色固体,熔点103-105℃;1H NMR(400MHz,CDCl3,25℃,TMS):δ8.34(1H,d,J=8.4Hz),8.19(2H,dt,J=8.4,2.0Hz),7.79(1H,d,J=8.0Hz),7.57(2H,d,J=8.4Hz),7.46(1H,td,J=8.4,1.2Hz),7.39(1H,td,J=8.0,1.2Hz),4.43(2H,q,J=7.2Hz),1.95(3H,s),1.43(3H,t,J=7.2Hz);13CNMR(100MHz,CDCl3,25℃,TMS):δ170.6,165.7,137.4(q,JC-F=4.1Hz),136.2,135.5,132.0,130.4,129.7,126.4,124.9,124.6,123.4(q,JC-F=267.2Hz),119.9(d,JC-F=1.7Hz),116.1,112.3(q,JC-F=34.7Hz),61.4,27.7,14.3;19F NMR(376MHz,CDCl3,25℃,TMS):δ-54.38;HRMS(ESI):m/z[M+Na]+calcd for(C20H16F3NO3)Na:398.0974;found:398.0979。
以上所述的实施例仅仅是对本发明的优选实施方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案作出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。

Claims (10)

1.一种N-乙酰-3-三氟甲基-2-苯基-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-吲哚化合物。
2.一种N-乙酰-3-三氟甲基-2-苯基-5-甲基-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰-4-甲基-苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-5-甲基-吲哚化合物。
3.一种N-乙酰-3-三氟甲基-2-苯基-5-甲氧基-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰-4-甲氧基-苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-5-甲氧基-吲哚化合物。
4.一种N-乙酰-3-三氟甲基-2-苯基-5-甲硫基-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰-4-甲硫基-苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-5-甲硫基-吲哚化合物。
5.一种N-乙酰-3-三氟甲基-2-苯基-6-氯-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰-3-氯-苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-6-氯-吲哚化合物。
6.一种N-乙酰-3-三氟甲基-2-苯基-5,6-二氯-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰-3,4-二氯-苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-5,6-二氯-吲哚化合物。
7.一种N-乙酰-3-三氟甲基-2-苯基-5-硝基-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰-4-硝基-苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-苯基-5-硝基-吲哚化合物。
8.一种N-乙酰-3-三氟甲基-2-(4-氯苯基)-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基-4-氯-苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-(4-氯苯基)-吲哚化合物。
9.一种N-乙酰-3-三氟甲基-2-(4-甲基苯基)-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基-4-甲基-苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-(4-甲基苯基)-吲哚化合物。
10.一种N-乙酰-3-三氟甲基-2-(4-乙酯基苯基)-吲哚的制备方法,其特征在于,向反应试管中分别依次加入乙酰苯胺,2.5mol%催化剂二氯(五甲基环戊二烯基)合铑(III)二聚体,2.0equiv氧化剂醋酸铜,10mol%添加剂六氟锑酸银和2mL溶剂叔戊醇,最后加入2.0equiv三氟甲基-4-乙酯基-苯乙炔,用橡胶塞密封反应试管,把试管置于100℃油浴中搅拌加热1小时左右,反应过程中用TLC检测至完全反应,后处理时先将溶剂旋干,直接上硅胶柱层析分离得纯净的产物N-乙酰-3-三氟甲基-2-(4-乙酯基苯基)-吲哚化合物。
CN201510527880.2A 2015-08-25 2015-08-25 一种3位三氟甲基取代吲哚的制备方法 Expired - Fee Related CN105130872B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510527880.2A CN105130872B (zh) 2015-08-25 2015-08-25 一种3位三氟甲基取代吲哚的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510527880.2A CN105130872B (zh) 2015-08-25 2015-08-25 一种3位三氟甲基取代吲哚的制备方法

Publications (2)

Publication Number Publication Date
CN105130872A CN105130872A (zh) 2015-12-09
CN105130872B true CN105130872B (zh) 2018-01-30

Family

ID=54716507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510527880.2A Expired - Fee Related CN105130872B (zh) 2015-08-25 2015-08-25 一种3位三氟甲基取代吲哚的制备方法

Country Status (1)

Country Link
CN (1) CN105130872B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
CN109851598B (zh) * 2019-02-15 2022-11-29 江西师范大学 三氟甲基取代反式烯醇酯的制备方法
CN112209867B (zh) * 2020-08-28 2022-07-19 绍兴文理学院 一种2-炔基取代吲哚类化合物的合成方法
CN113387863B (zh) * 2021-07-08 2022-11-22 康化(上海)新药研发有限公司 一种3-(三氟甲基)-4-吲哚甲酸的制备方法
CN113527173B (zh) * 2021-08-30 2022-12-16 河南师范大学 Heck串联反应合成吲哚萜类似物的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660806A (zh) * 2004-12-15 2005-08-31 上海大学 2-三氟甲基吲哚的合成方法
CN1869022A (zh) * 2006-06-27 2006-11-29 上海大学 5-甲氧基-2-三氟甲基吲哚及其合成方法
CN1927834A (zh) * 2006-07-21 2007-03-14 上海大学 6-氟-2-三氟甲基吲哚及其制备方法
CN101987832A (zh) * 2009-08-02 2011-03-23 温州大学 2-三氟甲基吲哚衍生物的制备方法
CN103641765A (zh) * 2004-06-24 2014-03-19 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5201660B2 (ja) * 2007-12-27 2013-06-05 独立行政法人産業技術総合研究所 4−トリフルオロメチルインドール−3−酢酸
EA026371B8 (ru) * 2012-07-17 2017-06-30 Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед Индолкарбонитрилы в качестве модуляторов рецептора андрогенов

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103641765A (zh) * 2004-06-24 2014-03-19 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
CN1660806A (zh) * 2004-12-15 2005-08-31 上海大学 2-三氟甲基吲哚的合成方法
CN1869022A (zh) * 2006-06-27 2006-11-29 上海大学 5-甲氧基-2-三氟甲基吲哚及其合成方法
CN1927834A (zh) * 2006-07-21 2007-03-14 上海大学 6-氟-2-三氟甲基吲哚及其制备方法
CN101987832A (zh) * 2009-08-02 2011-03-23 温州大学 2-三氟甲基吲哚衍生物的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Facile Regiocontrol in the Palladium-Catalyzed Annulation of Fluorine-Containing Internal Alkynes with Variously Substituted 2-Iodoanilines: A New Regioselective Synthesis of 2- or 3-Fluoroalkylated Indole Derivatives;Tsutomu Konno,et al;《J.Org.Chem.》;20041028;第69卷;第8258-8265页 *
Rh(III)-catalyzed coupling of nitrones with alkynes for the synthesis of indolines;Lingheng Kong,et al;《Chinese Journal of Catalysis》;20150720;第36卷;第925–932页 *
铑(III)催化吲哚甲酰胺衍生物与末端炔烃的C—H活化/环化反应;王亮,等;《有机化学》;20150109;第35卷;第688-697页 *

Also Published As

Publication number Publication date
CN105130872A (zh) 2015-12-09

Similar Documents

Publication Publication Date Title
CN105130872B (zh) 一种3位三氟甲基取代吲哚的制备方法
Kou et al. Asymmetric aza-Wacker-type cyclization of N-Ts hydrazine-tethered tetrasubstituted olefins: synthesis of pyrazolines bearing one quaternary or two vicinal stereocenters
Singh Recent advances in C–H bond functionalization with ruthenium-based catalysts
She et al. Synthesis of trisubstituted isoxazoles by palladium (II)-catalyzed cascade cyclization–alkenylation of 2-alkyn-1-one O-methyl oximes
Zhang et al. Cu (I)-catalyzed cross-coupling of terminal alkynes with trifluoromethyl ketone N-tosylhydrazones: access to 1, 1-difluoro-1, 3-enynes
Colby et al. Rhodium catalyzed chelation-assisted C–H bond functionalization reactions
Panda et al. Stereoselective synthesis of enamides by Pd-catalyzed hydroamidation of electron deficient terminal alkynes
Xia et al. Copper-catalyzed oxidative cyclization of enynes for the synthesis of 4-carbonyl-quinolines with O2
Wen et al. Rhodium-catalyzed [4+ 3] annulations of sulfoximines with α, β-unsaturated ketones leading to 1, 2-benzothiazepine 1-oxides
Huang et al. Sustainable difluoroalkylation cyclization cascades of 1, 8-enynes
Chechik-Lankin et al. Regiocontrolled carbometallation reactions of ynamides
Zemtsov et al. Copper-catalyzed allylation of α, α-difluoro-substituted organozinc reagents
Ishida et al. Copper-Catalyzed Domino [1, 3]/[1, 2] Rearrangement for the Efficient Synthesis of Multisubstituted ortho-Anisidines
Pirali et al. Ammonium chloride promoted three-component synthesis of 5-iminooxazoline and its subsequent transformation to macrocyclodepsipeptide
Gopalakrishnan et al. Diastereoselective Pd (II)-Catalyzed sp3 C–H Arylation Followed by Ring Opening of Cyclopropanecarboxamides: Construction of anti β-Acyloxy Carboxamide Derivatives
CN102358739B (zh) 咪唑[1,2-a]吡啶和咪唑醛类化合物的合成方法
Duan et al. NH4I-Triggered [4+ 2] Annulation of α, β-Unsaturated Ketoxime Acetates with N-Acetyl Enamides for the Synthesis of Pyridines
Miura et al. Ruthenium-catalyzed addition of aromatic amides to internal alkynes and subsequent intramolecular cyclization for the atom-economical synthesis of isoindolinones
Yu et al. Palladium-Catalyzed Decarboxylative Coupling of Alkynyl Carboxylic Acids and Alkenyl Tosylates for the Synthesis of Enynones
Herath et al. Continuous-flow synthesis of highly functionalized imidazo-oxadiazoles facilitated by microfluidic extraction
Liu et al. Palladium-catalyzed aminocarbonylation of alkynes to succinimides
Guo et al. Asymmetric transfer hydrogenation of 3-(trifluoromethyl) quinolines
Furukawa et al. Visible-light-driven direct 2, 2-difluoroacetylation using an organic pigment catalyst
CN105384731B (zh) 一种手性含胺甲基吡啶噁唑啉的化合物及其制备方法
Spulak et al. Direct C− H Arylation and Alkenylation of 1-Substituted Tetrazoles: Phosphine As Stabilizing Factor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180130

Termination date: 20190825